[go: up one dir, main page]

WO2002028869A1 - Inhibiteurs de la gamma-glutamyle transpeptidase - Google Patents

Inhibiteurs de la gamma-glutamyle transpeptidase Download PDF

Info

Publication number
WO2002028869A1
WO2002028869A1 PCT/US2001/031225 US0131225W WO0228869A1 WO 2002028869 A1 WO2002028869 A1 WO 2002028869A1 US 0131225 W US0131225 W US 0131225W WO 0228869 A1 WO0228869 A1 WO 0228869A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
halogen
carcinoma
aryl
glutamyl transpeptidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031225
Other languages
English (en)
Inventor
Robert E. London
Scott A. Gabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
US Department of Health and Human Services
Original Assignee
National Institutes of Health NIH
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, US Department of Health and Human Services filed Critical National Institutes of Health NIH
Priority to AU2001296637A priority Critical patent/AU2001296637A1/en
Publication of WO2002028869A1 publication Critical patent/WO2002028869A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Definitions

  • This invention relates to enzymatic inhibitors, particularly ⁇ -glutamyl transpeptidase inhibitors.
  • Tumor cell resistance to anti-neoplastic agents is a major obstacle to the successful treatment of most cancers. Therefore, methods or techniques that compromise the ability of cancer cells to resist anti-neoplastic agents are potentially important to the treatment of cancer.
  • Glutathione is a ubiquitous tripeptide that has a prominent role in many cellular functions, including the detoxification of some biologically active molecules. Increased amounts of intracellular glutathione are associated with tumor resistance to chemotherapy or radiation therapy, and, correspondingly, tumors with low or repressed levels of intracellular glutathione are more sensitive to chemotherapy and radiation treatments. See, e.g., Suzukake, K., et al., Biochem. Pharmacol, 31 :121-24 (1982); Green, J. A., et al, Cancer Res., 44:5427-31 (1984).
  • the membrane-bound enzyme ⁇ -glutamyl transpeptidase ( ⁇ -GT) plays a central role in the metabolism of glutathione.
  • ⁇ -GT is expressed in some cancers, may be induced in response to anticancer drugs or radiation therapy, and has been used as a marker for cell transformation and tumor growth. Additionally, ⁇ -GT may accelerate tumor growth and increase the resistance of tumors to chemotherapeutic agents. Hanigan, M.H., et al, Carcinogenesis, 20(4):553-59 (1999). A number of hypotheses about ⁇ -GT's physiological function have been proposed, but the best characterized in vivo function for ⁇ -GT involves metabolism and transport of glutathione and its derivatives. See, e.g., Hahn, R., et al., Biochem. Biophys. Ada., 539:324-37 (1978); Griffith, O.
  • ⁇ -GT helps regulate glutathione metabolism by recycling cysteine (one of the three peptides in the glutathione molecule). Additionally, under certain conditions, ⁇ -GT may facilitate the biosynthesis of ⁇ -glutamyl-cysteine (a glutathione precursor). Prezioso, J. A., et al., Int. J. Radiation Oncology Biol. Phys., 30:373-81 (1994).
  • ⁇ -GT appears to function as a threonine protease.
  • the mechanism of action for ⁇ -GT involves an intermediate transition state where a ⁇ - glutamyl is bound to a threonine residue located in the active site and on the lower molecular weight subunit of the enzyme.
  • Various studies with rat, porcine, and human ⁇ -GT enzymes and acivicin, a nonspecific irreversible ⁇ -GT inhibitor show that this threonine residue in the active site is esterif ⁇ ed during inhibition. Therefore, it is likely that this esterif ⁇ cation blocks the active site of ⁇ -GT, rather than inactivating a critical catalytic amino acid residue.
  • ⁇ -GT inhibitors are known, in addition to acivicin. Most of these previously described ⁇ -GT inhibitors are irreversible inhibitors. Such irreversible inhibitors include azaserine (O-diazoacetyl-L-serine), DON (6-diazo-5- oxo-norleucine), acivicin, and L-2-amino-4-fluorophosphono butanoic acid. Two reversible ⁇ -GT inhibitors have been described: L- ⁇ -glutamyl-(o-
  • anthglutin Carboxy)Phenylhydrazine (commonly called "anthglutin”) and ⁇ -(L- ⁇ -azaglutamyl)- L-cysteinyl-glycine.
  • anthglutin ⁇ -(L- ⁇ -azaglutamyl)- L-cysteinyl-glycine.
  • these reversible inhibitors have only moderate inhibitory activity, presumably because these compounds function as substrate analogs.
  • at least one study of anthglutin shows this compound is toxic to mice. Griffith, O. W., and Meister, A., Proc. Natl. Acad. Sci. USA. 76:268-72 (1979).
  • L-serine has been shown to inhibit ⁇ -GT in vitro in the presence of boronate buffer, apparently as a serine-boronate complex that acts as a transition state analog.
  • this serine-boronate complex requires the presence of a boronate buffer, which is not normally found under physiological conditions.
  • This invention relates to compounds and methods of inhibiting ⁇ -glutamyl transpeptidase ( ⁇ -GT) by contacting ⁇ -GT with an effective inhibitory amount of a compound having the formula:
  • R 0 is optional and may be H or lower alkyl
  • R t is H or lower alkyl
  • R 2 is H or lower alkyl
  • R 3 is H or halogen
  • R 4 is H or halogen
  • Z is B or C
  • W O when Z is C, or -OH when Z is B; Y is -OH, lower alkyl, -OPO 3 , -(CH 2 ) n -CO 2 , aryl, or CR 5 R 6 R 7 ; where R 5 is H, halogen, -PO 3 H 2 , -(CH 2 ) hinder-CO 2 , or -(CH 2 ) lake-aryl; R 6 is H, halogen, -PO 3 H 2 , -(CH 2 ) n -CO 2 , or -(CH 2 ) n -aryl; R 7 is H, halogen, -PO 3 H 2 , -(CH 2 ) n -CO 2 , or -(CH 2 ) n -aryl; and where at least one of R 5 , R 6 , or R 7 is halogen, and n is 1-8, for example 1-5, or any of 1, 2, 3, 4, 5, 6, 7 or 8. In particular embodiments,
  • Particular embodiments employ compounds that are L-isomers, D-isomers, or mixtures of both L- and D-isomers.
  • Exemplary compounds include L-2-amino-4- boronobutanoic acid (ABBA); 6,6,6-trifluoro-5-oxo-L-norleucine; and 6,6-difluoro- 5-oxo-6-phosphono-L-norleucine.
  • ABBA L-2-amino-4- boronobutanoic acid
  • 6,6,6-trifluoro-5-oxo-L-norleucine 6,6-difluoro- 5-oxo-6-phosphono-L-norleucine.
  • These compounds may inhibit ⁇ -GT associated with a cell, such as ⁇ -GT located on a cell membrane, or ⁇ -GT that is isolated apart from a cell.
  • the compound effectively inhibits ⁇ -GT with an inhibition constant (Kj) of about 8000 nM or less.
  • Certain embodiments include treating a condition or disease mediated by ⁇ - GT, or a condition or disease where toxicity of glutathione adducts may be a concern.
  • some neoplasms may be treated by administering a therapeutic amount of a ⁇ -GT inhibitor, particularly if the neoplasm expresses higher than normal levels of ⁇ -GT.
  • the neoplasm may inherently express ⁇ -GT at a heightened level, or such heightened expression may be induced by some environmental stimulus, such as radiation or a chemical agent.
  • the ⁇ -GT inhibitor also may inhibit neoplastic resistance to chemotherapy and radiotherapy, or potentiate the effects of radiation and certain chemotherapeutic agents.
  • the neoplasm is a carcinoma.
  • Particular carcinomas may, for example, arise in the kidney, lung, liver, prostate, breast, or thyroid.
  • the carcinoma is selected from the group consisting of adenocarcinomas and other carcinomas, for example renal cell carcinoma, lung adenocarcinoma, pleura mesothelioma, stomach adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, ovarian surface epithelial carcinoma, uterine serous papillary carcinoma, mammary invasive ductal carcinoma, mammary invasive lobular carcinoma, thyroid follicular carcinoma, thyroid papillary carcinoma, and combinations thereof.
  • adenocarcinomas and other carcinomas for example renal cell carcinoma, lung adenocarcinoma, pleura mesothelioma, stomach adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, ovarian surface epithelial carcinoma, uterine serous papillary carcinoma, mammary invasive ductal
  • the compound may be a pharmaceutically acceptable acid addition, salt, ester, or prodrug; or comprise 6a pharmaceutically acceptable carrier, agent, counterion, adjuvant, or vehicle.
  • the compound also may be administered in combination with another useful pharmaceutical agent or another ⁇ -GT inhibitor.
  • FIG. 1 A illustrates the transition state of ⁇ -GT.
  • FIG. IB illustrates a ternary complex formed from ⁇ -GT and serine in the presence of borate buffer.
  • FIG. 1C illustrates the interaction of ABBA with the active site of ⁇ -GT.
  • FIG. 2 illustrates the chemical interactions that occur during ⁇ -GT inhibition by ABBA.
  • FIG. 3 A is a Lineweaver-Burk plot of ABBA determined for varying substrate concentrations.
  • FIG. 3B is a replot of FIG. 2 A with the slopes of the lines determined in FIG. 2A plotted against the inhibitor (ABBA) concentration.
  • an inhibitor includes single or plural inhibitors and can be considered equivalent to the phrase “at least one inhibitor.”
  • an “animal” is a living multicellular vertebrate organism, a category which includes, for example, mammals, reptiles, arthropods, and birds.
  • Adduct refers to a compound produced by mixing two or more chemicals, including complexes that form when a chemical binds to a biological molecule.
  • amino refers to a chemical functionality -NR 1 R 2 , where Ri and
  • R 2 are independently hydrogen, alkyl, or aryl.
  • An "analog” is a molecule that differs in chemical structure from a parent compound. Examples include, but are not limited to: a homolog (which differs by an increment in the chemical structure, such as a difference in the length of an alkyl chain); a molecular fragment; a structure that differs by one or more functional groups; or a change in ionization. Structural analogs are often found using quantitative structure activity relationships (QSAR), with techniques such as those disclosed in Remington: The Science and Practice of Pharmacology, 19 l Edition (1995), chapter 28.
  • a derivative is a biologically active molecule derived from the base molecular structure.
  • a mimetic is a biomolecule that mimics the activity of another biologically active molecule.
  • Biologically active molecules can include both chemical structures and peptides that mimic the ⁇ -GT inhibitory activities of the compounds disclosed herein.
  • alkylamino refers to a lower alkyl radical appended to an -NH radical.
  • alkoxy refers to a substituted or unsubstituted alkoxy, where an alkoxy has the structure -O-R, where R is a substituted or unsubstituted alkyl. In an unsubstituted alkoxy, the R is an unsubstituted alkyl.
  • substituted alkoxy refers to a group having the structure -O-R, where R is alkyl which is substituted with a non-interfering substituent.
  • Lower alkoxy refers to any alkoxy in which R is a lower alkyl.
  • Thioalkoxy refers to -S-R, where R is substituted or unsubstituted alkyl.
  • alkoxyalkyl refers to an alkoxy group appended to a lower alkyl radical.
  • alkyl refers to a cyclic, branched, or straight chain alkyl group containing only carbon and hydrogen, which, unless otherwise described, contains one to twelve carbon atoms. This term is further exemplified by groups such as methyl, ethyl, n-propyl, isobutyl, t-butyl, pentyl, pivalyl, heptyl, adamantyl, and cyclopentyl.
  • Alkyl groups can be unsubstituted or substituted with one or more substituents, for example halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
  • substituents for example halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
  • aryl refers to a monovalent unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl, benzyl) or multiple condensed rings (e.g., naphthyl or anthryl), which can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, mercapto (-SH), alkylthio, trifluoromethyl, acyloxy, hydroxy, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
  • Cancer is a general term referring to diseases characterized by uncontrollable, abnormal growth of a cell.
  • a cancer may be a malignant neoplasm.
  • a “carcinoma” is a malignant neoplasm of epithelial tissue.
  • carbonyl containing group refers to -RCOR groups wherein R is alkyl, lower alkyl, hydroxyl, or secondary, tertiary, or quaternary amine, and R' is alkylene, such as methylene (- CH 2 -). Examples include -COOH, -CH 2 COOH, -CH 2 COOCH 3 , -CH 2 CONH 2 , and -CH 2 CON(CH 3 ) 2 .
  • Carboxyl refers to the radical -COOH, and substituted carboxyl refers to -COR where R is alkyl, lower alkyl, or a carboxylic acid or ester.
  • Conjugate refers to an acid and a base that can convert to each other by the gain or loss of a proton.
  • dialkylamino refers to -N-R-R' wherein R and R are independently selected from lower alkyl groups.
  • dialkylaminoalkyl refers to -N-R-R, which is appended to a lower alkyl radical, wherein R and R are independently selected from lower alkyl groups.
  • halogen refers to the elements fluourine, bromine, chlorine, and iodine
  • halo refers to fluoro, bromo, chloro and iodo substituents.
  • heterocycle refers to a monovalent saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., benzyl, morpholino, pyridyl or furyl), or multiple condensed rings (e.g., naphthyl, quinolinyl, indolizinyl or benzo[b]thienyl), and having at least one heteroatom, (defined as N, O, P, or S) within the ring.
  • a single ring e.g., benzyl, morpholino, pyridyl or furyl
  • multiple condensed rings e.g., naphthyl, quinolinyl, indolizinyl or benzo[b]thienyl
  • heteroatom defined as N, O, P, or S
  • a heterocycle can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1- yl, piperazin-1-yl, or other functionality.
  • Examples include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl.
  • heterocyclicalkyl refers to a heterocyclic group appended to a lower alkyl radical including, but not limited to, pyrrolidinylmethyl and morpholinylmethyl.
  • Hydrophill refers to -OH.
  • Hydroalkyl refers to -R-OH, wherein R is alkylene, especially lower alkylene (for example in methylene, ethylene, or propylene).
  • a hydroxyalkyl group may be either linear or branched, such as 1-hydroxyisopropyl.
  • labile refers to a chemical bond that is capable of changing state or being destroyed by application of relatively low amounts of energy. Labile bonds exist for short periods of time, such as seconds, minutes, or even a few hours. Non- labile bonds exist for longer periods of time, such as about 5 hours, or indefinitely. Ionic bonds and hydrogen bonds are inherently labile. Most covalent bonds are non- labile, though some exceptions exist. A covalent bond between oxygen and boron, such as a borate ester, is just one example of a labile covalent bond. However, a carbon-boron covalent bond is considered to be non-labile.
  • lower alkyl refers to a cyclic, branched or straight chain monovalent alkyl radical of one to six carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i- butyl (or 2-methylpropyl), sec-butyl, n-pentyl, cyclopropylmethyl, i-amyl, n-amyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n- hexyl. Lower alkyl groups can be unsubstituted or substituted. One specific example of a substituted alkyl is 1,1 -dimethyl propyl.
  • lower alkenyl refers to a straight or branched chain alkyl radical containing from two to six carbon atoms and also having one carbon-carbon double bond including, but not limited to: vinyl, 2-propenyl, 2-methyl-2-propenyl, 3- butenyl, 4-pentenyl, and 5-hexenyl.
  • a “mammal” includes both human and non-human mammals.
  • Neoplasm refers to a new and abnormal growth of tissue, which may be benign or malignant.
  • a “pharmaceutical agent,” “pharmaceutical composition,” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
  • the pharmaceutically acceptable salts of the compounds of this invention include, but are not limited to, those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl- glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
  • These salts may be prepared by standard procedures, for example by reacting the free acid with a suitable organic or inorganic base. Any chemical compound recited in this specification may
  • phenyl refers to a phenyl group, which may be unsubstituted or substituted with a substituent selected from lower alkyl, alkoxy, thioalkoxy, hydroxy and halo.
  • phenylalkyl refers to a phenyl group appended to a lower alkyl radical including, but not limited to, benzyl, 4-hydroxybenzyl, 4-chlorobenzyl, and 1 -naphthylmethyl.
  • prodrug refers to a compound that is converted within the body to a more active form that has medicinal or therapeutic effects.
  • reversible refers to a chemical reaction capable of proceeding in either of two directions, in contast to an "irreversible” chemical reaction that can proceed in only one direction.
  • a reversible inhibitor of an enzyme is characterized by an ability to readily, even rapidly, dissociate from the enzyme-inhibitor complex.
  • an irreversible enzymatic inhibitor becomes tightly bound to the enzyme (either covalently or noncovalently) and dissociates slowly from the target enzyme.
  • An irreversible inhibitor will usually form an adducf with the target enzyme, for example, via the formation of a non-labile covalent bond between the inhibitor and enzyme.
  • An irreversible inhibitor that has bound to the target enzyme cannot be isolated apart from the target enzyme in any substantial amount after the inhibition interaction. If the enzyme is then digested by a protease (such as chymotripsin), one or more amino acids of the enzyme may remain attached to the irreversible inhibitor.
  • a reversible inhibitor usually will not form an adduct with the target enzyme and can be more readily isolated apart from the target enzyme after the inhibition interaction.
  • stable compound refers to a compound that is sufficiently stable to survive isolation to a useful degree of purity from a reaction mixture and formulation into a therapeutic dosage form suitable for administration.
  • subject includes both human and veterinary subjects, such as primates, canines, felines, and rodents.
  • terapéuticaally effective amount refers to an amount or dose sufficient to inhibit the enzymatic activity of ⁇ -GT and is capable of relieving symptoms associated with ⁇ -GT activation or expression.
  • thioalkoxyalkyl refers to a thioalkoxy group appended to a lower alkyl radical.
  • the invention includes embodiments of a compound (according to Formula A below) and a method for inhibiting ⁇ -glutamyl transpeptidase ( ⁇ -GT) by contacting ⁇ -GT with an effective inhibitory amount of the compound.
  • ⁇ -GT ⁇ -glutamyl transpeptidase
  • Y is -OH, lower alkyl, -OPO 3 , -(CH 2 ) n -CO 2 , -(CH 2 ) n -aryl, or CR 5 R 6 R 7 ;
  • R 5 is H, halogen, -PO 3 H 2 , -(CH 2 ) hurry-CO 2 , or -(CH 2 ) n -aryl;
  • R 6 is H, halogen, -PO 3 H 2 , -(CH 2 ) n -CO 2 , or -(CH 2 ) n -aryl;
  • R 7 is H, halogen, -PO 3 H 2 , -(CH 2 ) n -CO 2 , or -(CH 2 ) deliberately-aryl; and where at least one of R 5 , R 6 or R 7 is halogen, and n is 1-8, for example 1-5, or any of 1, 2, 3, 4, 5, 6, 7 or 8.
  • the aryl is a benzyl, for example a substituted benzyl.
  • a -(CH 2 ) n -aryl where the aryl is a substituted benzyl is:
  • CO 2 " is a carboxyl, but also could be a substituted carboxyl.
  • Specific embodiments employ compounds of Formula A wherein Z is B and W is -OH; Y is -OH, -(CH 2 ) n -CO 2 , or -(CH 2 ) n -aryl, such as
  • at least one of R 3 , R f , R 5 , R 6 and R 7 is halogen, such as F.
  • at least one of R 3 and R 4 and at least one of R 5 and R 6 are halogen, such as F.
  • Z is B, W is -OH, and Y is -(CH 2 ) deliberately-CO 2 , or -(CH 2 ) n -aryl, such as
  • Z is B; and both W and Y are -OH.
  • Other embodiments employ compounds of Formula A wherein
  • R7 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Table 1 illustrates some particular known compounds of Formula A.
  • All of these compounds may be either L- or D-isomers, though particular embodiments employ compounds that are L-isomers, D-isomers, or mixtures of both L- and D-isomers.
  • the compound is a reversible inhibitor of ⁇ -GT.
  • ABBA is a reversible and effective ⁇ -GT inhibitor (see Example 1 below).
  • the mechanism of inhibition involves a compound that is a structural analog of glutamic acid or glutamine and mimics the transition state of the enzyme.
  • the ⁇ - GT active site contains a nucleophile, such as the hydroxyl of a threonine (e.g., Thr 391 in the E. coli ⁇ -GT), which interacts and bonds with the compound.
  • FIG. 1 A illustrates the transition state of ⁇ -GT.
  • FIG. IB illustrates a ternary complex formed by the interaction of serine and ⁇ -GT in the presence of borate buffer. This serine-borate complex can weakly inhibit ⁇ -GT at millimolar concentrations. Tate, S. S. and Meister, A., Proc. Natl. Acad. Sci. USA 75(10):4806- 09 (1978). Serine in a borate buffer will rarely bond with borate molecules. However, if ⁇ -GT is added, the ⁇ -GT may independently interact with serine and borate, and the serine and borate may be brought together in the ⁇ -GT active site to form a serine-borate complex. As illustrated in FIG.
  • this complex forms a labile covalent bond between the boron of the boronic acid and the hydroxyl oxygen of the serine.
  • This labile bond is considered to be a serine-borate oxygen ester linkage.
  • the ⁇ -GT itself stabilizes this serine-borate complex in the active site. However, if either the serine or borate dissociates from the active site, the serine-borate complex will fall apart because the labile serine-borate oxygen ester linkage is not normally strong enough to hold the serine and borate together.
  • a boronic compound according to Formula A (i.e., where Z is boron) has a non-labile bond, since a carbon takes the place of the serine hydroxyl oxygen in the labile serine-borate oxygen ester linkage. This carbon-boron bond is considered to be non-labile.
  • Other compounds according to Formula A i.e., where Z is carbon
  • a compound according to Formula A is a more stable inhibitor of ⁇ -GT, compared to the serine-borate complex with the enzyme, and will demonstrate more potent inhibition of ⁇ -GT compared to the ternary complex illustrated in FIG. IB.
  • ABBA has a non-labile methylene boronate linkage, rather than the labile boron-oxygen bond between the serine and borate portions of the ternary complex illustrated in FIG. IB.
  • FIG. 2 The chemistry of the interaction between ABBA and ⁇ -GT is further illustrated in FIG. 2.
  • Other compounds according to Formula A form similar bonds with the active site nucleophile, though the nucleophile bonds to a carbonyl carbon rather than boron.
  • the nucleophile e.g., the hydroxyl of the threonine in the active site
  • Some compounds according to Formula A inhibit ⁇ -GT at nanomolar concentrations.
  • Certain embodiments employ a compound according to Formula A that inhibits ⁇ -GT at a K ⁇ value less than about 8000 nM.
  • Other embodiments provide even more effective inhibition of ⁇ -GT, such as inhibiting ⁇ -GT at a Kj value less than about 5000 nM, less than about 2500 nM, less than about 1000 nM, less than about 500 nM, less than about 250 nM, less than about 100 nM, less than about 50 nM, or less than about 25 nM.
  • ABBA inhibits ⁇ -GT with a Kj value of about 17 nM, as demonstrated in Example 1.
  • ketones which typically undergo nucleophilic addition during chemical reaction.
  • these compounds may interact with a nucleophile in the ⁇ -GT active site (e.g., a hydroxyl of threonine) through the carbonyl-carbon.
  • Electron- withdrawing substituents, such as fluorine, added to the carbonyl-carbon will enhance this nucleophilic attraction.
  • a ketone according to Formula A will have a tetrahedral geometiy around the carbonyl group, if the compound is hydrated. Such a tetrahedral geometry provides a structural basis for inhibiting ⁇ -GT, in addition to the functional nature of the carbonyl group as a site for nucleophilic addition.
  • Certain embodiments of the invention relate to inhibiting the activity of ⁇ -GT that is located within a cell, such as on a cell membrane, including (but not limited to) in situ studies of ⁇ -GT activity, or in vivo assays using cell cultures.
  • the cell may be immortalized, such as a cell isolated from a cell culture arising from a neoplasm.
  • the cell may be of a particular tissue type, such as a kidney cell or white blood cell.
  • Alternative embodiments encompass inhibiting the activity of ⁇ -GT that is not associated with a cell, such as measuring the enzyme kinetics of ⁇ -GT in vitro.
  • the ⁇ -GT will be isolated away from other biomolecules.
  • the isolated ⁇ -GT may be inhibited in a liposome or similar environment.
  • ⁇ -GT inhibitor according to Formula A is administered in a therapeutically effective amount to a subject.
  • Such embodiments are particularly useful in conditions or diseases that are mediated by ⁇ -GT, or conditions or diseases where toxicity of glutathione adducts or conjugates may be a concern.
  • Some neoplasms may be treated by administering a therapeutic amount of a compound according to Formula A.
  • Some neoplasms express ⁇ -GT, and may express ⁇ -GT at heightened levels compared to other tissues. This heightened expression of ⁇ -GT may be a natural expression of the neoplasm, or may be induced by some environmental stimulus, such as radiation or chemical agents.
  • the ⁇ -GT adopts an intracellular orientation, rather than the typical extracellular orientation, thus enhancing the ability of the neoplastic cells to recycle cysteine and glutathione. Therefore, in certain embodiments, the compound according to Formula A is transported into the cell to contact the ⁇ -GT intracellularly.
  • the ⁇ -GT inhibitor compound may inhibit growth of the neoplasm if administered in therapeutically effective amounts.
  • Tumors to be treated with the ⁇ - GT inhibitor may be selected, for example, by determining whether the tumor overexpresses ⁇ -GT, including using the method shown in Hanigan, M. H., Human Pathology, 30(3):300-05 (1999).
  • Examples of ⁇ -GT overexpressmg tumors include lung adenocarcinoma, mammary invasive ductal carcinoma, hepatocellular carcinoma, and prostate adenocarcinoma.
  • Individual subjects can be selected for treatment by the inhibitors disclosed herein based on pathological diagnosis that the individual has a tumor type that usually overexpresses ⁇ -GT.
  • ⁇ -GT levels of individual tumors can be measured to determine whether ⁇ -GT levels are increased in a particular tumor, in which case treatment with the inhibitor may be initiated.
  • the compound is administered in association with another anti-neoplastic treatment.
  • anti-neoplastic treatments include anti-neoplastic chemotherapy or radiotherapy.
  • the neoplasm may become resistant to the chemotherapy and/or radiotherapy via expression of ⁇ -GT.
  • the ⁇ -GT inhibitor also may inhibit neoplastic resistance to chemotherapy and radiotherapy.
  • the ⁇ -GT inhibitor potentiates the effects of radiation and certain drugs.
  • Glutatliione may protect cells against radiation and certain drugs, such as cisplatin.
  • the compounds according to Formula A may beneficially potentiate the effects of radiation and other agents on cells.
  • Renal toxicity may result from exposure to environmental, pharmacological, or other xenobiotic agents that form glutathione adducts or conjugates in vivo.
  • adducts or conjugates may be subsequently degraded in the kidney by ⁇ -GT.
  • chemotherapeutic agents e.g., cisplatin, doxorubicin
  • Cells of the kidney may metabolize glutathione conjugates or adducts to recover cysteine, and metabolism of glutathione adducts or conjugates can lead to chemical species, such as mercapturic acids, that are more reactive and exhibit greater toxicity than the adduct or conjugate itself.
  • the method includes embodiments where inhibiting ⁇ -GT using a compound according to Formula A decreases metabolism of glutathione conjugates or adducts and, in turn, reduces renal toxicity.
  • the neoplasm is a carcinoma.
  • Particular carcinomas may arise in certain organs or tissues, such as the kidney, lung, liver, prostate, breast, or thyroid.
  • the carcinoma is selected from the group consisting of adenocarcinomas and other carcinomas, for example renal cell carcinoma, lung adenocarcinoma, stomach adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, ovarian surface epithelial carcinoma, uterine serous papillary carcinoma, mammary invasive ductal carcinoma, mammary invasive lobular carcinoma, thyroid follicular carcinoma, thyroid papillary carcinoma, and combinations thereof.
  • neoplasms exhibiting increased ⁇ -GT enzyme are selected for treatment.
  • Overexpression of ⁇ -GT can be determined by immunocytochemistry, in situ hybridization, RT-PCR, or in situ PCR.
  • ⁇ -GT expression can be detected by immunostaining with GGT129, an affinity- produced polyclonal antibody directed against a 20-amino-acid peptide corresponding to the C-terminus of the heavy subunit of human ⁇ -GT.
  • ⁇ -GT activity can be assayed biochemically using ⁇ -glutamyl-p-nitroanilide as a substrate and measuring . amounts of the resulting p-nitroanilide using spectrophotometry. See, e.g., Wright, E. C, et al., J. Inher. Metab. Dis., 2-7 (1979); see also Example 1 below.
  • the compound may be a pharmaceutically acceptable acid addition, salt, ester, or prodrug. Additionally, the compound may include a pharmaceutically acceptable carrier, agent, counterion, adjuvant, or vehicle. In some embodiments, the compound may be orally bioavailable and/or stable under physiological conditions, such as physiological pH.
  • Some embodiments include administering another useful pharmaceutical agent, such as a pharmaceutical agent useful for treating the condition or disease.
  • glutathione represents a defensive mechanism of a neoplastic cell against radiation or chemotherapy
  • some embodiments include administering a ⁇ -GT inhibitor according to Formula A in combination with another inhibitor of glutathione synthesis (e.g., ⁇ -glutamyl cysteine synthetase, glutamine synthetase).
  • the ⁇ -GT inhibitor can be used in combination with buthionine sulfoximine (BSO), an inhibitor of ⁇ -glutamyl cysteine synthetase.
  • BSO buthionine sulfoximine
  • Particular embodiments employ another ⁇ -GT inhibitor, such as a currently known ⁇ -GT inhibitor; another ⁇ -GT inhibitor according to Formula A; or another antineoplastic agent specifically used to treat a particular carcinoma (e.g., taxol or vinblastine in the treatment of a lung carcinoma, tamoxifen or doxorubicin in the treatment of breast carcinoma, or methotrexate in the treatment of ovarian carcinoma).
  • a particular carcinoma e.g., taxol or vinblastine in the treatment of a lung carcinoma, tamoxifen or doxorubicin in the treatment of breast carcinoma, or methotrexate in the treatment of ovarian carcinoma.
  • L-2-amino-4-borono butanoic acid (ABBA), an amino acid analog, was demonstrated to be an effective ⁇ -GT inhibitor.
  • FIG. 1 A illustrates the proposed transition state of ⁇ -GT.
  • the enzyme binding site contains a positively charged group interacting with the ⁇ -carboxyl, an anionic group interacting with the ⁇ -amino, and an N-terminal threonine residue (Thr in the E. coli ⁇ -GT) forming a tetrahedral adduct with the ⁇ -carbonyl.
  • FIG. IB the proposed mechanism of inhibition for a serine-borate buffer mixture involves the formation of a ternary enzyme-L-serine-borate complex that functions as a transition state analog. The labile serine-boronate ester linkage is stabilized by the interaction with the enzyme.
  • FIG. 1 A illustrates the proposed transition state of ⁇ -GT.
  • the enzyme binding site contains a positively charged group interacting with the ⁇ -carboxyl, an anionic group interacting with the ⁇ -amino, and an N-terminal threonine residue (Thr in the E.
  • ABBA replaces this labile serine-boronate ester linkage with a non-labile methylene boronate linkage, resulting in more potent inhibition of ⁇ -GT. Since ABBA contains this non-labile carbon-boron bond, it can reversibly form a complex with ⁇ -GT via the tetrahedral boronate group, which presumably links directly to the threonine oxygen in the active site. This interaction mimics the transition state complex formed by the enzyme. ABBA was obtained from Paradigm Organics (Raleigh, NC). ⁇ -GT, derived from bovine kidney, was obtained from Sigma (St.
  • FIG. 3 A is a Lineweaver-Burke plot with an apparent Michaelis constant of
  • ABBA is a more effective inhibitor compared to known reversible ⁇ -GT inhibitors.
  • the L-isomer of anthglutin has a reported inhibition constant of 8.2 ⁇ M (8200 nM), while the D-isomer of anthglutin has a reported inhibition constant of 22.5 ⁇ M (22,500 nM).
  • Two rat liver cell lines were obtained from Dr. Michael Meredith (Oregon Health Sciences University, Portland, OR): nontumorigenic ARL-15C ⁇ and tumorigenic ARL-16T 2 .
  • ARL-lSCi contained low levels of ⁇ -GT
  • ARL- 16T 2 contained high levels of ⁇ -GT.
  • Both cell lines were cultured using Williams Media E (WME), with 10% fetal calf serum.
  • WME Williams Media E
  • the WME was aspirated from the plates ' after the initial 24 hour growth period and replaced with a modified WME that contained no cysteine or low cysteine (0.05 mM), plus 10% fetal calf serum. Half the cells were also treated with 10 ⁇ M ABBA.
  • ⁇ -GT inhibitors include, for example, encapsulation in liposomes, microparticles, microcapsules, and receptor-mediated endocytosis. See, e.g., Wu and Wu, J Biol. Chem., 262:4429-32 (1987).
  • an attractive feature of ⁇ -GT as a drug target is its localization on the outer surface of most cells. Therefore, any ⁇ -GT inhibitor that enters the bloodstream should eventually come into contact with a ⁇ -GT molecule; the ⁇ -GT inhibitor is not required to cross the cell membrane in order to interact with a ⁇ -GT molecule in a normal extracellular orientation.
  • ⁇ -GT may adopt an intracellular orientation and, in this case, the ⁇ -GT inhibitor usually must enter the cell in order to inhibit the ⁇ -GT.
  • Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes.
  • the compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • compositions of the invention may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment, for example, by local infusion during surgery; topical application, such as in conjunction with a wound dressing after surgery; by injection; through a catheter; or by a suppository or an implant, such as a porous, non-porous, or gelatinous material, including membranes, such as silastic membranes, or fibers.
  • administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.
  • liposomes as a delivery vehicle is one delivery method.
  • the liposomes fuse with the target site and deliver the contents of the lumen intracellularly.
  • the liposomes are maintained in contact with the target cells for a sufficient time for fusion to occur, using various means to maintain contact, such as isolation and binding agents.
  • Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes, such as Sendai virus or influenza virus.
  • the lipids may be any useful combination of known liposome forming lipids, including cationic lipids, such as phosphatidylcholine. Other potential lipids include neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.
  • the procedure described by Kato et al., J Biol. Chem., 266:3361-64 (1991) may be used.
  • compositions include a therapeutically effective amount of the ⁇ -GT inhibitor and a pharmaceutically acceptable carrier or excipient.
  • Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the carrier and composition can be sterile, and the formulation can suit the mode of administration.
  • the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate.
  • the composition is formulated in accordance with routine procedures, such as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition also may include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule, indicating the quantity of active agent.
  • compositions may be administered intravenously in any conventional medium for intravenous injection, such as an aqueous saline medium, or in blood plasma medium.
  • the medium also may contain conventional pharmaceutical adjunct materials such as, for example: pharmaceutically acceptable salts to adjust the osmotic pressure; lipid carriers, such as cyclodextrins; proteins, such as serum albumin; hydrophilic agents, such as methyl cellulose; detergents; buffers; preservatives; and the like.
  • pharmaceutically acceptable salts to adjust the osmotic pressure such as an aqueous saline medium, or in blood plasma medium.
  • lipid carriers such as cyclodextrins
  • proteins such as serum albumin
  • hydrophilic agents such as methyl cellulose
  • detergents buffers
  • preservatives and the like.
  • compositions can be prepared with conventional pharmaceutically acceptable carriers, adjuvants and counterions.
  • the compositions are in the form of a unit dose in solid, semi-solid, or liquid dosage form, such as tablets, pills, powders, liquid solutions, or suspensions.
  • compositions can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2- ethylamino ethanol, histidine, and procaine.
  • ⁇ -GT The amount of ⁇ -GT that will be effective in the treatment of a particular disease or condition will depend on the nature of the disease or condition, and can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or condition, and should be decided according to the judgment of the practitioner and each subject's or patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro, in vivo, or animal model test systems.
  • the pharmaceutical compositions may be stored or carried within a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products. The notice also may reflect approval by the agency of manufacture, use, or sale for human administration.
  • the specific dose level and frequency of dosage for any particular subject may be varied and will depend on a variety of factors, including the activity of the specific compound; the metabolic stability and length of action of that compound; the age, body weight, general health, sex, diet of the subject; the mode and time of administration; rate of excretion; drug combination; and severity of the condition of the subject undergoing therapy.
  • compositions or methods of treatment may be administered in combination with other therapeutic treatments, such as other antineoplastic therapies.
  • the ⁇ -GT inhibitors may be administered in combination with effective doses of other antineoplastic compounds, other ⁇ -GT inhibitors, or inhibitors of glutathione biosynthesis generally (e.g., BSO).
  • the ⁇ -GT inhibitors also may be administered in combination with radiation therapy, chemotherapy, or surgical therapy.
  • administration includes both concurrent and sequential administration of the active agents, and the ⁇ -GT inhibitors may be administered in combination with any composition (such as a chemotherapeutic agent), radiation, or surgical procedure for the treatment of neoplasms.
  • compositions that may be administered in combination with the ⁇ -GT inhibitors include (but are not limited to) antimetabolites, plant alkaloids, topoisomerase inhibitors, alkylating agents, and antitumor antibiotics, such as: fluoracil, gemcitabine, methotrexate, carboplatin, cisplatin, paclitaxel, vinorelbine, doxorubicin, etoposide, mitoxantrone, cyclophosphamide, ifosfamide, mitomycin C, and dacarbazine.
  • antimetabolites such as: fluoracil, gemcitabine, methotrexate, carboplatin, cisplatin, paclitaxel, vinorelbine, doxorubicin, etoposide, mitoxantrone, cyclophosphamide, ifosfamide, mitomycin C, and dacarbazine.
  • ionizing radiation such as x-rays or gamma rays, using teletherapy or brachytherapy
  • particle beam therapy using neutron or proton beams A more complete explanation of antineoplastic therapies can be found in Harrison 's Principals of Internal Medicine (14th ed., 1998) in chapter 86.
  • Antineoplastic agents which are being used in combination with ⁇ -GT inhibitor therapy (e.g., ABBA therapy), can be clinically used in accepted clinical protocols, for example, those given in the Physician 's Desk Reference (1999 Ed.) and in Goodman and Gilman, The Pharmacological Basis of Therapeutics, Section XIII, Chemotherapy ofNeoplastic Disease by Calabresi and Parks, pp. 1240-1306 (7 th Ed. 1985, Macmilian Publishing Co, New York).
  • Methods of selecting ⁇ -GT inhibitors useful for treating cancer may be determined by in vitro pharmacosensitivity tests. Such tests employ well known methods of assaying in vitro activity for selecting compounds appropriate for in vivo uses. Examples of known assaying methods include the methods disclosed in U.S. Pat. Nos. 5,736,129 and 5,270,172.
  • Example 6 Reducing Renal Toxicity of Chemotherapeutic Agents Griffith and Meister (Proc. Natl. Acad. Sci. USA, 76(l):268-72 (1979)) have administered a ⁇ -GT inhibitor, ⁇ -glutamyl(o-caboxy)phenylhdrazide, to mice (0.5 mmol/kg) and found that this level of adminstration blocked the metabolism of labeled ⁇ -glutamyl-L-a-amino[14C]butyrate. Based on its much stronger inhibition constant determined in vitro, administration of 0.01-0.1 mM/kg of ABBA is sufficient to block renal ⁇ -GT activity for a period of several hours.
  • a ⁇ -GT inhibitor ⁇ -glutamyl(o-caboxy)phenylhdrazide
  • a chemotherapeutic agent such as cisplatin
  • a chemotherapeutic agent such as cisplatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé pour inhiber la η-glutamyle transpeptidase (ηGT), au moyen d'un inhibiteur réversible et efficace. L'acide L-2-amino-4-buronobutanoïque (ABBA), la difluoro-6,6-oxo-5-phosphono-6-L-norleucine et la trifluoro-6,6,6-oxo-5-L-norleucine constituent des exemples d'inhibiteurs. L'invention concerne également un procédé pour traiter un état ou une maladie provoqués par la η-GT, tels qu'un état ou une maladie caractérisés par une surexpression de la η-GT. Le procédé consiste également à traiter un état ou une maladie dans lesquels la toxicité rénale résulte d'une exposition à des agents environnementaux, pharmacologiques, ou à d'autres agents xénobiotiques qui forment des adduits ou des conjugués de glutathione qui sont par la suite dégradés dans le rein par la η-GT. Dans certains exemples, l'état ou la maladie est un néoplasme.
PCT/US2001/031225 2000-10-05 2001-10-04 Inhibiteurs de la gamma-glutamyle transpeptidase Ceased WO2002028869A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001296637A AU2001296637A1 (en) 2000-10-05 2001-10-04 Gamma-glutamyl transpeptidase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23832000P 2000-10-05 2000-10-05
US60/238,320 2000-10-05

Publications (1)

Publication Number Publication Date
WO2002028869A1 true WO2002028869A1 (fr) 2002-04-11

Family

ID=22897390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031225 Ceased WO2002028869A1 (fr) 2000-10-05 2001-10-04 Inhibiteurs de la gamma-glutamyle transpeptidase

Country Status (2)

Country Link
AU (1) AU2001296637A1 (fr)
WO (1) WO2002028869A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233772A4 (fr) * 1999-11-19 2004-06-16 Topgene Inc Composes et complexes de bore utilises comme agents anti-inflammatoires
WO2008137446A1 (fr) * 2007-05-03 2008-11-13 Trustees Of Boston University Procédés et compositions pour le traitement des maladies respiratoires
IT201800010907A1 (it) 2018-12-10 2020-06-10 Stazione Zoologica Anton Dohrn 5-tioistidine e derivati metilati (ovotioli) come inibitori di attività gammaglutamil-transpeptidasi (ggt)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009825A1 (fr) * 1997-08-29 1999-03-04 Elan Pharmaceuticals, Inc. Procede servant a prevenir la mort de neurones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009825A1 (fr) * 1997-08-29 1999-03-04 Elan Pharmaceuticals, Inc. Procede servant a prevenir la mort de neurones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFITH, OWEN W. ET AL: "Selective inhibition of.gamma.-glutamyl-cycle enzymes by substrate analogs", PROC. NATL. ACAD. SCI. U. S. A., vol. 74, no. 8, 1977, pages 3330 - 3334, XP001050456 *
LONDON, ROBERT E. ET AL: "Development and Evaluation of a Boronate Inhibitor of.gamma.- Glutamyl Transpeptidase", ARCH. BIOCHEM. BIOPHYS., vol. 385, no. 2, 2001, pages 250 - 258, XP001050426 *
STEIN, ROSS L. ET AL: "Slow-binding inhibition of.gamma.- glutamyl transpeptidase by.gamma.-boroGlu", BIOCHEMISTRY, vol. 40, no. 19, 2001, pages 5804 - 5811, XP001050567 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233772A4 (fr) * 1999-11-19 2004-06-16 Topgene Inc Composes et complexes de bore utilises comme agents anti-inflammatoires
WO2008137446A1 (fr) * 2007-05-03 2008-11-13 Trustees Of Boston University Procédés et compositions pour le traitement des maladies respiratoires
IT201800010907A1 (it) 2018-12-10 2020-06-10 Stazione Zoologica Anton Dohrn 5-tioistidine e derivati metilati (ovotioli) come inibitori di attività gammaglutamil-transpeptidasi (ggt)
EP3666760A1 (fr) 2018-12-10 2020-06-17 Stazione Zoologica "Anton Dohrn" Composés de 5-thioistidine et dérivés méthylés (ovothiols) en tant qu'inhibiteurs de l'activité de gamma-glutamyl-transpéptidase (ggt)

Also Published As

Publication number Publication date
AU2001296637A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
Coulter et al. Mitochondrially targeted antioxidants and thiol reagents
WO2009025781A1 (fr) Activateurs de la pyruvate kinase m2 et procédé de traitement d'une maladie
US20190321495A1 (en) Compositions and methods of treating melanoma
ES2219607T3 (es) Nuevo agente inhibidor de la urocinasa.
PT721465E (pt) Compostos activados pela glutationa s-transferase
US10729669B2 (en) Compositions and methods for treating cancer
CN101199501A (zh) Hif羟化酶抑制剂
Holstein A patent review of bisphosphonates in treating bone disease
BRPI0710796A2 (pt) 12-imidazolil-1-dodecanol e seus sais farmaceuticamente aceitáveis, uso dos mesmos na produção de preparação farmacêutica, e preparação farmacêutica compreendendo os referidos compostos e sais
US20250064995A1 (en) Psma targeted compounds and uses thereof
MX2010010867A (es) Composicion farmaceutica.
Hamdan et al. Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176
Kestell et al. Disposition of Amsacrine and Its Analogue 9-({; 2-Methoxy-4-[(methylsulfonyl)-amino] phenyl} amino)-N, 5-dimethyl-4-acridinecarboxamide (CI-921) in Plasma, Liver, and Lewis Lung Tumors in Mice
WO2002028869A1 (fr) Inhibiteurs de la gamma-glutamyle transpeptidase
PT2271332E (pt) Uso de compostos no tratamento de tauopatias
BR112014026948B1 (pt) Composto de fórmula (i), método para a preparação de um composto da fórmula (i), composição farmacêutica e composto da fórmula (i)
JP2011513395A (ja) 酵素の構造、活性、及び／又は、発現レベルの調節
Huang et al. Protection of normal brain cells from γ-irradiation-induced apoptosis by a mitochondria-targeted triphenyl-phosphonium-nitroxide: a possible utility in glioblastoma therapy
US8318798B2 (en) Therapeutic agent for neurodegenerative disease
US20100028417A1 (en) Use of substituted glycerin derivatives for producing a pharmaceutical preparation
US6143737A (en) Progesterone analogs to reverse multidrug resistance
US20080021015A1 (en) Use as medicine of a compound restoring active principles in vivo
KR101400505B1 (ko) Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
US7056908B2 (en) Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
US20110082087A1 (en) Compounds for treating pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP